Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of psychedelics in mental health, with J&J aiming for $3-3.5 billion annual sales by 2027-2028 and peak sales up to $5 billion. The report also notes upcoming milestones for other psychedelic developers like Compass Pathways and AtaiBeckley, suggesting growing investor interest and regulatory support in the sector.
Five established companies—Johnson & Johnson, PepsiCo, Coca-Cola, Exxon Mobil, and Kimberly-Clark—have declared new dividends backed by decades of consistent payout increases. Each company recently reported strong earnings or raised guidance, signali...
Johnson & Johnson's stock reached $270.24, close to its 52-week high of $276.47, following raised full-year guidance and FDA approval of a new robotic surgical system. The company shows strong growth in oncology and immunology, with key products like...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
With the 10-Year Treasury yield at 4.74%, dividend stocks must offer durable income. Dividend Aristocrats, companies with 25+ years of dividend increases, remain reliable for retirement income. Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo,...
The FDA has approved IMAAVY (nipocalimab-aahu) for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older, marking the first therapy specifically proven safe and effective for this rare, life-threatening disease. IMAAVY works...
